BioNTech (NASDAQ:BNTX) Stock Price Down 1.6% – Here’s What Happened

BioNTech SE (NASDAQ:BNTX) fell 1.6% during trading on Friday . The company traded as low as $117.76 and last traded at $118.75. 98,963 shares were traded during mid-day trading, a decline of 88% from the average session volume of 806,475 shares. The stock had previously closed at $120.69.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BNTX. Canaccord Genuity Group increased their price objective on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Bank of America increased their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Wells Fargo & Company began coverage on shares of BioNTech in a research report on Wednesday. They set an “overweight” rating and a $170.00 target price for the company. Finally, UBS Group lifted their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $140.76.

BioNTech Trading Down 0.2 %

The company has a fifty day simple moving average of $113.91 and a two-hundred day simple moving average of $100.17. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $28.64 billion, a PE ratio of -56.55 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. Analysts anticipate that BioNTech SE will post -3.72 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Slow Capital Inc. lifted its position in shares of BioNTech by 12.0% in the second quarter. Slow Capital Inc. now owns 51,080 shares of the company’s stock valued at $4,105,000 after acquiring an additional 5,467 shares in the last quarter. Van ECK Associates Corp grew its position in BioNTech by 1.9% during the second quarter. Van ECK Associates Corp now owns 119,901 shares of the company’s stock valued at $9,635,000 after acquiring an additional 2,192 shares during the period. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV raised its holdings in BioNTech by 41.4% in the second quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 20,500 shares of the company’s stock valued at $1,647,000 after buying an additional 6,000 shares during the period. TD Asset Management Inc lifted its position in BioNTech by 6.1% during the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after buying an additional 435 shares in the last quarter. Finally, Candriam S.C.A. grew its stake in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.